<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="./datadict_v2.xsl"?><data_table id="pht003502.v1" study_id="phs000611.v1" participant_set="1" date_created="Tue Jan  7 08:13:11 2014"><variable id="phv00195710.v1"><name>SUBJID</name><description>De-identified subject ID</description><type/></variable><variable id="phv00195711.v1"><name>RACE</name><description>Subject's race</description><type>encoded value</type><value code="AA">African American</value><value code="C">Caucasian, non Hispanic</value></variable><variable id="phv00195712.v1"><name>GENDER</name><description>Subject's gender</description><type>string</type></variable><variable id="phv00195713.v1"><name>CLINICAL RECEPTOR STATUS</name><description>ER, HER2 receptor status</description><type>string</type></variable><variable id="phv00195714.v1"><name>SITES OF DISEASE</name><description>Metastatic disease sites [BR=breast; CNS=brain; BN=bone; L=lung; A=adrenal; CT=cutaneous; PL=pleura; PC=pericardium; N=nodes; H=liver]</description><type>string</type></variable><variable id="phv00195715.v1"><name>DRUG TREATMENTS</name><description>Systemic treatment history</description><type>string</type><comment>[DOC=docetaxel; DOX=doxorubicin; DOX-L= doxorubicin liposomal; CTX=cyclophosphamide; PAC=paclitaxel; NAV=navelbine; GEM=gemcitabine; EPI=epirubicin; 5FU=5-Fluorouracil; NAB-P=nab-paxlitaxel; CP=carboplatin; CAP=capecitabine; IXA=ixabepilone; LAP-lapatinib; HER=trastuzumab; BEV=bevacizumab; FAS=fulvestrant; GOS=goserelin; TAM=tamoxifen; EXM=exemestane; ANA=anastrozole; LET=letrozole; CCI-779=temsirolomus; EST=estradiol; MEG=megace; MET=methotrexate; PI3K-INH=PI3 Kinase inhibitor phase I trial; NER=neratinib; RAL=raloxifene; ERI =eribulin; CIS=cisplatin; PAT=patupilone; EVR=everolimus; GSO=graft sample obtained]</comment><value code="CIS">cisplatin</value><value code="ERI">eribulin</value><value code="EVR">everolimus.</value><value code="NER">neratinib</value><value code="PAT">patupilone</value><value code="RAL">raloxifene</value></variable><variable id="phv00195716.v1"><name>OVERALL SURVIVAL</name><description>Post-diagnosis survival</description><type>integer</type><unit>Months</unit></variable><variable id="phv00195717.v1"><name>FAMILY HISTORY: BREAST, OVARIAN</name><description>Relatives diagnosed with breast or ovarian cancer</description><type>string</type></variable></data_table>
